首页> 外文会议>International Symposium on IgA Nephropathy >Clinicopathological Influence of Obesity in IgA Nephropathy: Comparative Study of 74 Patients
【24h】

Clinicopathological Influence of Obesity in IgA Nephropathy: Comparative Study of 74 Patients

机译:肥胖对IgA肾病的临床病理学影响:74例比较研究

获取原文

摘要

The pathological role of obesity has rarely been studied in primary glomerular diseases. The purpose of this study is to examine the clinicopathological influence of obesity in IgA nephropathy (IgAN). 74 patients with IgA nephropathy in our institution from October 2000 to January 2004 were retrospectively divided into two groups according to body mass index (BMI): the non-obese group (group N) with BMI < 25 kg/m2, and the obese group (group O) with BMI s 25 kg/m2. There were 50 patients in group N and 24 patients in group O. Clinical analysis showed no significant difference between these two groups hi blood pressure, serum cholesterol, creatinine clearances or grade of hematuria. However, urinary protein excretion and serum creatinine were significantly greater in group O than in group N. Although semiquantitative analysis of light-microscopical findings showed no significant differences in the severity of mesangial proliferation, matrix expansion, glomerulosclerosis or crescent formation, image analysis showed that total glomerular area and tuft area were significantly larger in group O. In addition, ultrastructural study revealed significantly higher glomerular basement membrane thickness in group O. 62 patients (46 patients, group N; 16 patients, group O) were followed in our institution for one year. Urinary protein was significantly decreased only in patients who received steroid in both groups. Although administration of ACE inhibitor or ARB tended to decrease urinary protein in group O, the change was not statistically significant. Our findings indicate that obesity may accelerate the increase of proteinuria in IgAN through ultrastructural modification of the glomerular basement membrane.
机译:肥胖的病理作用却很少被研究的原发性肾小球疾病。这项研究的目的是研究肥胖的IgA肾病(IgA肾病)的临床病理影响。与BMI <25公斤/平方米,而肥胖组的非肥胖组(N组):74例在我们的机构从2000年10月至2004年1月IgA肾病根据体重指数(BMI)进行回顾性分为两组(组O)与BMI第25公斤/平方米。有50名患者在N组和24例在组O.临床分析表明这两个组。在血压,血清胆固醇,肌酐清除率或血尿的级之间没有显著差异。然而,尿蛋白排泄和血清肌酐均O组比组N.显著更大虽然光显微镜发现半定量分析显示在系膜增生,基质扩张,肾小球硬化症或新月体形成的严重性没有显著差异,图像分析表明总肾小球面积和簇面积均显著较大组O.此外,超微结构研究揭示组O. 62例在显著更高肾小球基底膜厚度(46例,组N; 16名患者,组O)随访在我们的机构一年。尿蛋白只在谁两组接受类固醇的患者被显著下降。虽然ACE抑制剂或ARB的给药倾向于在O组减少尿蛋白,变化没有统计学显著。我们的研究结果表明,肥胖会加速蛋白尿的IgA肾病中通过肾小球基底膜的超微结构的改变增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号